Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 49 articles:
HTML format

Single Articles

    January 2023
  1. ZHOU YB
    Pseudovesicular appearance in Sweet's syndrome: important yet easily missed.
    Lancet. 2023;401:104.

  2. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
    Pseudovesicular appearance in Sweet's syndrome: important yet easily missed - Authors' reply.
    Lancet. 2023;401:104.

  3. CHUA BH, Link EK, Kunkler IH, Olivotto IA, et al
    Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost? - Authors' reply.
    Lancet. 2023;401:24.

  4. MULLIEZ T, De Ridder M
    Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost?
    Lancet. 2023;401:23-24.

  5. MEROLA JF, Landewe R, McInnes IB, Mease PJ, et al
    Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
    Lancet. 2023;401:38-48.
    PubMed     Abstract available

    Bimekizumab in psoriatic arthritis: a great leap forward?
    Lancet. 2023;401:2-3.

  7. MCINNES IB, Asahina A, Coates LC, Landewe R, et al
    Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
    Lancet. 2023;401:25-37.
    PubMed     Abstract available

  8. MITJA O, Ogoina D, Titanji BK, Galvan C, et al
    Lancet. 2023;401:60-74.
    PubMed     Abstract available

    December 2022
  9. THYSSEN JP, Schmid-Grendelmeier P
    Long-term disease control in atopic dermatitis using biologics.
    Lancet. 2022 Dec 9:S0140-6736(22)02347-9. doi: 10.1016/S0140-6736(22)02347.

  10. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
    An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.
    Lancet. 2022 Dec 9:S0140-6736(22)02037-2. doi: 10.1016/S0140-6736(22)02037.
    PubMed     Abstract available

  11. RASSY E, Delaloge S
    A second-generation antibody-drug conjugate to treat HER2-positive breast cancer.
    Lancet. 2022 Dec 7:S0140-6736(22)02534-X. doi: 10.1016/S0140-6736(22)02534.

  12. HURVITZ SA, Hegg R, Chung WP, Im SA, et al
    Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
    Lancet. 2022 Dec 6:S0140-6736(22)02420-5. doi: 10.1016/S0140-6736(22)02420.
    PubMed     Abstract available

    November 2022
  13. SANCHEZ-MEZA E, Kubelis-Lopez DE, Ocampo-Candiani J, Chavez-Alvarez S, et al
    Prominent skin folds of the scalp provide a superficial clue in acromegaly.
    Lancet. 2022;400:1802.

  14. VRSELJA A, Latifi A, Baber RJ, Stuckey BGA, et al
    Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet. 2022;400:1704-1711.
    PubMed     Abstract available

  15. CRANDALL CJ, Ganz PA
    Phase 2 data on a new treatment for hot flushes in women with breast cancer.
    Lancet. 2022;400:1659-1661.

    October 2022

  16. Aqueous skin antisepsis before surgical fixation of open fractures (Aqueous-PREP): a multiple-period, cluster-randomised, crossover trial.
    Lancet. 2022;400:1334-1344.
    PubMed     Abstract available

    September 2022
  17. KIM S, Wuthrick E, Blakaj D, Eroglu Z, et al
    Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Lancet. 2022;400:1008-1019.
    PubMed     Abstract available

  18. SAIAG P, Blom A
    Combined nivolumab and ipilimumab in non-resectable Merkel cell carcinoma.
    Lancet. 2022;400:976-977.

  19. PALLER AS, Simpson EL, Siegfried EC, Cork MJ, et al
    Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2022;400:908-919.
    PubMed     Abstract available

  20. HALLING AS, Thyssen JP
    Biological therapy for young children with atopic dermatitis.
    Lancet. 2022;400:867-869.

  21. LIVINGSTONE E, Zimmer L, Hassel JC, Fluck M, et al
    Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
    Lancet. 2022 Sep 9. pii: S0140-6736(22)01654.
    PubMed     Abstract available

  22. SMITHY JW, Postow MA
    Adjuvant checkpoint blockade following complete local therapy for melanoma metastases.
    Lancet. 2022 Sep 9. pii: S0140-6736(22)01748.

    August 2022
    DRESS syndrome.
    Lancet. 2022;400:560.

  24. HINDIE E
    Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed?
    Lancet. 2022;400:559.

  25. LUKE JJ, Ibrahim N, Eggermont AM
    Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed? - Authors' reply.
    Lancet. 2022;400:559-560.

  26. CHUA BH, Link EK, Kunkler IH, Whelan TJ, et al
    Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
    Lancet. 2022;400:431-440.
    PubMed     Abstract available

  27. COLES CE, Chatterjee S, Jagsi R, Kirby AM, et al
    Breast radiotherapy for ductal carcinoma in situ: could less be more?
    Lancet. 2022;400:408-410.

    July 2022
  28. REICH K, Thyssen JP, Blauvelt A, Eyerich K, et al
    Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
    Lancet. 2022;400:273-282.
    PubMed     Abstract available

  29. MENNINI M, Di Nardo G, Fiocchi AG
    Atopic dermatitis: time for tailored therapy.
    Lancet. 2022;400:252-253.

  30. RUDD EC, Kulasekararaj A, Basu TN
    Facial lymphoedema, viral warts, and myelodysplastic syndrome: the protean condition of GATA2 deficiency.
    Lancet. 2022;400:236.

    June 2022
  31. SKJERVEN HO, Lie A, Vettukattil R, Rehbinder EM, et al
    Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial.
    Lancet. 2022;399:2398-2411.
    PubMed     Abstract available

  32. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
    Sweet's syndrome and Crohn's disease diagnosed simultaneously.
    Lancet. 2022;399:2155.

    May 2022
  33. HIBI T
    Risankizumab for Crohn's disease.
    Lancet. 2022;399:1992-1993.

  34. DANESE S, Vermeire S, Zhou W, Pangan AL, et al
    Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Lancet. 2022 May 26. pii: S0140-6736(22)00581.
    PubMed     Abstract available

  35. ABDELNABI M, Elmssary M, Sekhon J, Benjanuwattra J, et al
    Acute onset of fever, eosinophilia, rash, acute kidney injury, and a positive Monospot test in a patient on lamotrigine: DRESS syndrome.
    Lancet. 2022;399:1902.

    April 2022
  36. MEGALY M, Boshra N
    Pyogenic granuloma-like Kaposi's sarcoma.
    Lancet. 2022;399:e38.

  37. TCHERNEV G, Chokoeva AA
    Melanoma in a Chinese dragon tattoo.
    Lancet. 2022;399:e37.

    March 2022
  38. LUKE JJ, Rutkowski P, Queirolo P, Del Vecchio M, et al
    Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
    Lancet. 2022 Mar 31. pii: S0140-6736(22)00562.
    PubMed     Abstract available

  39. DRIVENES JL, Betz RC, Bygum A
    A girl with unruly locks: molecular genetics makes a diagnosis of uncombable hair syndrome.
    Lancet. 2022;399:1079.

  40. CRAIG T, Magerl M, Levy DS, Reshef A, et al
    Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2022;399:945-955.
    PubMed     Abstract available

  41. FIJEN LM, Levi M
    Prophylaxis with anti-activated factor XII for hereditary angioedema.
    Lancet. 2022;399:889-890.

    February 2022
  42. KUMAR A, Preston N, Phillips R
    Picturing health: Buruli ulcer in Ghana.
    Lancet. 2022;399:786-797.

  43. COLES CE, Anderson BO, Cameron D, Cardoso F, et al
    The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00184.

    December 2021
  44. AL-MATAR SH, Sairam C, Roussel L, Langelier MJ, et al
    Fever, abdominal pain, serositis, arthralgia, hearing loss, proteinuria, and a family history: Muckle Wells syndrome.
    Lancet. 2021;398:2101.

    November 2021
  45. MURPHY MJ, Damsky W, Vesely MD
    A pruritic psoriatic plaque develops at the donor site of an autologous skin graft: Koebner phenomenon.
    Lancet. 2021;398:1836.

    October 2021
  46. GONZALES E, Hardikar W, Stormon M, Baker A, et al
    Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
    Lancet. 2021;398:1581-1592.
    PubMed     Abstract available

    April 2021
  47. LOIBL S, Poortmans P, Morrow M, Denkert C, et al
    Breast cancer.
    Lancet. 2021 Apr 1. pii: S0140-6736(20)32381.
    PubMed     Abstract available

    March 2021
  48. WANG C, Li A, Shi Q, Yu Z, et al
    Metagenomic next-generation sequencing clinches diagnosis of leishmaniasis.
    Lancet. 2021;397:1213.

    January 2021

  49. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries.
    Lancet. 2021;397:387-397.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.